Pfizer to Launch Two Oncology Biosimilars at Lowest Wholesale Acquisition Cost in the US

Shots:

• Pfizer anticipates the launch of two oncology biosimilars, Ruxience (biosimilar, rituximab) & Trazimera (biosimilar, trastuzumab) at lowest WAC among all the biosimilars present in the market
• Pfizer will launch Ruxience today at WAC of $71.68/10mg or 24% discount to the WAC of Rituxan while Trazimera at WAC of $80.74/10 mg or 22% discount to the WAC of Herceptin. Zirabev was launched on Dec 31, 2019 at $61.34/10mg or 23% discount to the WAC of Avastin
• Ruxience referencing Roche’s Rituxan, available for NHL, CLL, GPA and MPA while Trazimera referencing Roche’s Herceptin, indicated for the treatment of HER2+ BC and HER2 overexpressing GE. Zirabev referencing Roche’s Avastin and is available to treat multiple cancer indications

Click here to­ read full press release/ article | Ref: Pfizer | Image: Pfizer